• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    •   

      The RINVOQ study program1

      RINVOQ demonstrated consistent clinical remission rates across patient populations studied1

      *RINVOQ is not indicated for MTX-naive patients.
      Primary endpoint: clinical remission (DAS28 [CRP]<2.6) compared to placebo.

      bDMARD: biological disease-modifying antirheumatic drug; csDMARD-IR: inadequate responder to conventional synthetic DMARDs; DAS28 (CRP): disease activity score with 28 joint count (C-reactive protein); DMARD: disease-modifying antirheumatic drug; MTX: methotrexate.

      Jeg vil gjerne ha mer informasjon fra en produktspesialist.

      Jeg har spørsmål til medisinsk avdeling.

        

      Felleskatalogteksten finner du her

      Referanser

      1. RINVOQ SPC avsnitt 5.1, sist oppdatert 21.05.2022.

       

      NO-RNQ-200012v2.0juni/2021